Literature DB >> 28369411

Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.

Christophe Hézode1,2, Slim Fourati3,2, Stéphane Chevaliez3,2, Giovanna Scoazec1, Alexandre Soulier3,2, Anne Varaut1, Murielle François1, Isaac Ruiz1,3,2, Françoise Roudot-Thoraval1, Ariane Mallat1,2, Jean-Michel Pawlotsky3,2.   

Abstract

We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  chronic hepatitis C; resistance; resistance-associated substitutions.; retreatment; sustained virological response

Mesh：

Substances：

Year:  2017        PMID： 28369411     DOI： 10.1093/cid/cix214

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

1.  Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure.

Authors:  Yousry Esam-Eldin Abo-Amer; Rehab Badawi; Mohamed El-Abgeegy; Heba Fadl Elsergany; Ahmed Abdelhaleem Mohamed; Sahar Mohamed Mostafa; Hatem Samir Alegaily; Shaimaa Soliman; Sally Elnawasany; Sherief Abd-Elsalam
Journal:  Adv Virol       Date:  2020-07-24

2.  Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure.

Authors:  Hala Mohamed; Weal Abd El Ghany; Reem Yehia; Magdy Fouad
Journal:  Clin Exp Hepatol       Date:  2022-03-23

3.  SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study.

Authors:  Naukhaiz Taqi Sheikh; Muhammad Taha Shaukat; Azhar Hussain; Ahmed Ayyan; Abdullah Iqbal; Shakiba Karim; Hasan Ilyas; Kaleem Ullah; Muhammad Junaid Tahir; Muhammad Sohaib Asghar
Journal:  Ann Med Surg (Lond)       Date:  2022-07-20

Review 4.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883

5.  Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.

Authors:  Fred Poordad; Stanislas Pol; Armen Asatryan; Maria Buti; David Shaw; Christophe Hézode; Franco Felizarta; Robert W Reindollar; Stuart C Gordon; Stephen Pianko; Michael W Fried; David E Bernstein; Joel Gallant; Chih-Wei Lin; Yang Lei; Teresa I Ng; Preethi Krishnan; Sarah Kopecky-Bromberg; Jens Kort; Federico J Mensa
Journal:  Hepatology       Date:  2018-01-30       Impact factor: 17.425

6.  The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures.

Authors:  Stephanie Popping; Valeria Cento; Carole Seguin-Devaux; Charles A B Boucher; Adolfo de Salazar; Eva Heger; Orna Mor; Murat Sayan; Dominique Salmon-Ceron; Nina Weis; Henrik B Krarup; Robert J de Knegt; Oana Săndulescu; Vladimir Chulanov; David A M C van de Vijver; Federico García; Francesca Ceccherini-Silberstein
Journal:  Viruses       Date:  2021-12-22       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.